Collagen Solutions PLC New Manufacturing Agreement
15 Gennaio 2019 - 8:00AM
RNS Non-Regulatory
TIDMCOS
Collagen Solutions PLC
15 January 2019
15 January 2019
Collagen Solutions plc
("Collagen Solutions", the "Company" or the "Group")
New Manufacturing Agreement for Excellagen(R) Collagen Wound
Healing Matrix
Collagen Solutions plc (AIM: COS), the developer and
manufacturer of biomaterials and regenerative medicines for the
enhancement and extension of human life, announces that it has
entered into a new agreement with Olaregen Therapeutix, Inc.
("Olaregen") to manufacture and produce Excellagen(R), an advanced
FDA 510(k)-cleared wound healing product indicated for the
treatment of hard to heal wounds such as diabetic foot ulcers.
The Company originally assisted in the development of and
manufactured Excellagen for Gene Biotherapeutics Inc. (formerly
Taxus Cardium Pharmaceuticals Group Inc.) prior to 2014, who had
been seeking a strategic partner for the launch of Excellagen(R).
Gene Biotherapeutics announced a transaction with Olaregen in
September 2018 covering the sale of Excellagen(R) for wound
healing. With these new agreements, Collagen Solutions is now
supporting Olaregen's launch of Excellagen(R) in the first half of
2019.
Wound care products are designed to cure and treat a variety of
complex wounds, both chronic and acute. Examples are diabetic foot
ulcers, venous and pressure ulcers, burns, trauma and others for
which Excellagen(R) is cleared for use. The rising incidence of
difficult to treat wounds, resulting from increasing prevalence of
diabetes and a rapidly ageing population, is driving growth in the
wound care space and encouraging developments and innovations in
enhanced wound care products, such as Excellagen(R).
Commenting on the win, Jamal Rushdy, CEO says: "We are delighted
to sign this contract with Olaregen and are excited to be part of
the Excellagen launch. This new agreement is consistent with our
strategy to move up the value chain by collaborating with industry
partners to develop and launch innovative products designed to
improve patients' lives."
"Olaregen is pleased to partner with the world class
manufacturer, Collagen Solutions, to manufacture Excellagen, our
initial product offering. We have the utmost confidence in Collagen
Solutions to provide us with a high-quality product that meets
mandated standards. This may be our most important partnership."
said Anthony J. Dolisi, CEO of Olaregen.
Enquiries:
Collagen Solutions Plc
Jamal Rushdy, CEO Via Walbrook
Hilary Spence, CFO
Cenkos Securities Plc (Nominated
Adviser and Broker)
Steve Cox (Corporate Finance) Tel: 0207 397 8900
Stephen Keys
Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Helen Cresswell Mob: 07841 917 679
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFEDLIISLIA
(END) Dow Jones Newswires
January 15, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Healthcare Inv (LSE:HIO)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Healthcare Inv (LSE:HIO)
Storico
Da Gen 2024 a Gen 2025
